Technology aids PK, PD predictions in virtual human and lab animal populations.
Certara has decided to acquire Simcyp and will thus gain a modeling and simulation platform for predicting the fate of drugs in virtual populations. Certara itself specializes in discovery and development software and consulting services.
“The capabilities offered by Simcyp’s preclinical technologies, combined with our existing software products and scientific consulting services, will provide significant drug development advantages to our mutual and prospective clients,” says Certara’s president and CEO, Jim Hopkins.
“From a translational science perspective, Simcyp’s preclinical simulation technologies, which include prediction of drug-drug interactions, fit perfectly between Certara’s existing discovery and clinical research offerings, thus enabling an end-to-end solution. For example, this means broader capabilities to predict drug disposition as a function of molecular structure and the ability to utilize a single unified suite of tools to facilitate preclinical and clinical PBPK and PKPD modeling and analysis.”
Simcyp’s platform integrates demographic, physiological, genomic, and in vitro biochemical data. This allows researchers to predict drug absorption and disposition in representative virtual patient populations including pediatrics. The company also offers consultancy and guidance on a broad spectrum of drug metabolism and pharmacokinetic issues. This includes advice on optimal design for metabolic drug-drug interaction studies, interpretation of data, and prediction of in vivo ADME from in vitro studies.
Certara was formed through the merger of Tripos, focused on improving the efficiency of molecular discovery, with Pharsight, focused on improving the preclinical and clinical development process. Both companies provide scientific software and consulting services.